2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study
Hamer M, McCarty J, Pierson B, Regules J, Mendy J, Sanborn A, Gardner C, Haller J, Gregory M, Liggett D, Glass P, Ghosh N, Royalty Tredo S, Warfield K, Burke C, Lee C, Saunders D, Bedell L, Richardson J. Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study. The Lancet Microbe 2025, 6: 101000. PMID: 39954701, DOI: 10.1016/j.lanmic.2024.101000.Peer-Reviewed Original ResearchGeometric mean titresCHIKV VLPsVaccine recipientsVLP vaccineAdverse eventsSex-matchedAlphavirus vaccinesOpen-labelParallel-groupAge-matchedVirus-like particlesPrimary immunogenicity endpointNeutralising antibodiesVEEV vaccinesAntibody seroconversion ratesPhase 2 randomised controlled trialFisher's exact testClinical study sitesStatistically significant differenceImmunogenicity endpointsSeroconversion ratesCompare immunogenicitySingle doseAntibody increaseExact test
2024
Efficient Genome Editing Using ‘NanoMEDIC’ AsCas12a-VLPs Produced with Pol II-Transcribed crRNA
Borovikova S, Shepelev M, Mazurov D, Kruglova N. Efficient Genome Editing Using ‘NanoMEDIC’ AsCas12a-VLPs Produced with Pol II-Transcribed crRNA. International Journal Of Molecular Sciences 2024, 25: 12768. PMID: 39684477, PMCID: PMC11641575, DOI: 10.3390/ijms252312768.Peer-Reviewed Original ResearchRNA ribonucleoprotein complexVirus-like particlesGenome editingProcesses pre-crRNARNA polymerase IIIEfficient genome editingTargeted genome editingJurkat T cellsGene therapy applicationsMature crRNAsPre-crRNAPolymerase IIICas nucleasesRibonucleoprotein complexEfficient targeted genome editingCrRNAMammalian cellsLevels of gene editingPackaging mechanismPromoter usageU6 promoterT cellsEditing efficiencyCXCR4 knockoutGene editingInducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation
Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F, Zhang Z, Anang S, Mothes W, Sodroski J, Kappes J. Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation. Journal Of Virology 2024, 98: e01720-24. PMID: 39508605, PMCID: PMC11650979, DOI: 10.1128/jvi.01720-24.Peer-Reviewed Original ResearchHuman immunodeficiency virusEnv trimersNeutralizing antibodiesHIV-1Virus-like particlesEnvelope glycoproteinEnv conformationImmunodeficiency virusInducible cell linesCell linesImmune systemEffective HIV/AIDS vaccineHIV-1 persistenceHuman immunodeficiency virus particlesEnvelope glycoprotein spikeHIV-1 EnvPoorly neutralizing antibodiesHIV-like particlesHIV-1 particlesDefective virus-like particlesHost immune systemEnv immunogensHIV/AIDS vaccineCreation of stable cell linesHost cell receptorsCarbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity
Lensch V, Gabba A, Hincapie R, Bhagchandani S, Basak A, Alam M, Noble J, Irvine D, Shalek A, Johnson J, Finn M, Kiessling L. Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity. ACS Nano 2024, 18: 26770-26783. PMID: 39283240, PMCID: PMC11646345, DOI: 10.1021/acsnano.4c07360.Peer-Reviewed Original ResearchCellular immunityDendritic cellsToll-like receptorsVirus-like particlesCD8<sup>+</sup> T cellsTumor-specific cellular immunityVaccine developmentCancer vaccine developmentInfiltrate solid tumorsMurine melanoma modelT cell functionInhibited tumor growthActivate TLR signalingTumor controlCancer immunotherapyCD4<sup>+</sup>Melanoma modelTLR7 agonistDC activationT cellsSolid tumorsTumor cellsTumor growthHumoral immunityVLP platformBeta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice
Ullah I, Symmes K, Keita K, Zhu L, Grunst M, Li W, Mothes W, Kumar P, Uchil P. Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice. Vaccines 2024, 12: 1007. PMID: 39340037, PMCID: PMC11435481, DOI: 10.3390/vaccines12091007.Peer-Reviewed Original ResearchImmune responseVirus-like particlesBeta spikesCross-protective immune responsesSARS-CoV-2 immunitySARS-CoV-2Effective immune responseEffective humoral immune responseHumoral immune responseAncestral spikeT cellsVaccination regimenSARS-CoV-2 virus-like particlesVaccine platformMouse modelVariant spike proteinsOmicron spikeBeta variantDisease burdenNon-infectiousReduce virus spreadImmunityVariant spikesFusion glycoproteinSpike proteinThe RRE-REV module has no effect on the packaging efficiency of cas9 and Gag proteins into nanomedic virus-like particles
Kruglova N, Komkov D, Mazurov D, Shepelev M. The RRE-REV module has no effect on the packaging efficiency of cas9 and Gag proteins into nanomedic virus-like particles. Доклады Российской Академии Наук Науки О Жизни 2024, 515: 64-70. DOI: 10.31857/s2686738924020121.Peer-Reviewed Original ResearchRev expression plasmidVirus-like particlesEmpty control plasmidGene therapy of human diseasesGag proteinTherapy of human diseasesGene therapyViral Gag proteinTarget cellsControl plasmidProtein levelsCas9 nucleaseGenome editingGagEfficiency of genome editingMethods of genome editingExpression of Cas9Plasmid constructsCotransfectionHuman diseasesPlasmidCell lysatesNuclear export
2023
The RRE–Rev Module Has No Effect on the Packaging Efficiency of Cas9 and Gag Proteins into NanoMEDIC Virus-like Particles
Kruglova N, Komkov D, Mazurov D, Shepelev M. The RRE–Rev Module Has No Effect on the Packaging Efficiency of Cas9 and Gag Proteins into NanoMEDIC Virus-like Particles. Doklady Biological Sciences 2023, 513: s45-s50. PMID: 38472686, DOI: 10.1134/s0012496623700886.Peer-Reviewed Original ResearchConceptsRev expression plasmidVirus-like particlesRev response elementEmpty control plasmidGene therapy of human diseasesGag proteinTherapy of human diseasesCas9 nucleaseGene therapyGenome editingGag expressionViral Gag proteinHIV Rev response elementTarget cellsEfficiency of genome editingMethods of genome editingControl plasmidProtein levelsNuclear exportNO effectPlasmid modificationGagResponse elementAccessory proteinsPlasmid constructsHIV-1 Env trimers asymmetrically engage CD4 receptors in membranes
Li W, Qin Z, Nand E, Grunst M, Grover J, Bess J, Lifson J, Zwick M, Tagare H, Uchil P, Mothes W. HIV-1 Env trimers asymmetrically engage CD4 receptors in membranes. Nature 2023, 623: 1026-1033. PMID: 37993716, PMCID: PMC10686830, DOI: 10.1038/s41586-023-06762-6.Peer-Reviewed Original ResearchConceptsHIV-1 Env trimersCD4 moleculeHuman immunodeficiency virus-1 (HIV-1) infectionEnv trimersAntibody-mediated immune responsesEnv-CD4 interactionVirus-1 infectionVaccine immunogen designViral envelope glycoproteinsHIV-1Immune responseCD4 receptorImmunogen designEnvelope glycoproteinVirus-like particlesCD4EnvHost cell membraneBacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle
Nand K, Jordan T, Yuan X, Basore D, Zagorevski D, Clarke C, Werner G, Hwang J, Wang H, Chung J, McKenna A, Jarvis M, Singh G, Bystroff C. Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle. Vaccine 2023, 41: 6791-6801. PMID: 37833124, DOI: 10.1016/j.vaccine.2023.09.044.Peer-Reviewed Original ResearchConceptsVirus-like particlesSperm hyperactivated motilityHuman papilloma virusInclusion bodiesLong-acting protectionCalcium ion channelsNon-hormonal interventionsContraceptive efficacyHyperactivated motilityPapilloma virusPrincipal pieceSperm tailContraceptive vaccineBALB/c miceHypervariable regionCatSperVaccine antigensBacterial productionVaccine candidatesIon channelsIn vitroVaccinePregnancyRecombinant vaccineExtracellular loop
2022
Generation of Multiple Arbovirus-like Particles Using a Rapid Recombinant Vaccinia Virus Expression Platform
Wang Y, Griffiths A, Brackney D, Verardi P. Generation of Multiple Arbovirus-like Particles Using a Rapid Recombinant Vaccinia Virus Expression Platform. Pathogens 2022, 11: 1505. PMID: 36558839, PMCID: PMC9785247, DOI: 10.3390/pathogens11121505.Peer-Reviewed Original ResearchVirus-like particlesTransmission electron microscopyRecombinant vaccinia virus expression systemVirus expression systemExpression platformVaccinia virus expression systemElectron microscopyGenetic modificationVLP formationExpression systemNative virionsPlatformSignal sequenceCapsid geneParticlesGenesMicroscopyRe-emerging arbovirusHeartland virusWestern blotVLP secretionPurificationThrombocytopenia syndrome virusExpressionMayaro virus
2020
Intestinal Virome in Patients With Alcoholic Hepatitis
Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura‐Cots M, Bataller R, Bosques‐Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia‐Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology 2020, 72: 2182-2196. PMID: 32654263, PMCID: PMC8159727, DOI: 10.1002/hep.31459.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderAlcoholic hepatitisDisease severityEnd-stage liver disease (MELD) scoreFecal samplesLiver Disease scoreMulticenter observational studyVirus-like particlesHigher median ModelIntestinal viromeLiver diseaseSevere manifestationsAntibiotic treatmentObservational studyDisease scoreUse disordersPatientsHigh mortalityViral diversityGut bacteriaViral microbiomeMortalitySeverityHepatitisCD300lf is the primary physiologic receptor of murine norovirus but not human norovirus
Graziano VR, Walker FC, Kennedy EA, Wei J, Ettayebi K, Strine MS, Filler RB, Hassan E, Hsieh LL, Kim AS, Kolawole AO, Wobus CE, Lindesmith LC, Baric RS, Estes MK, Orchard RC, Baldridge MT, Wilen CB. CD300lf is the primary physiologic receptor of murine norovirus but not human norovirus. PLOS Pathogens 2020, 16: e1008242. PMID: 32251490, PMCID: PMC7162533, DOI: 10.1371/journal.ppat.1008242.Peer-Reviewed Original ResearchConceptsMNoV infectionPrimary physiologic receptorPhysiologic receptorHuman norovirusMurine norovirusBona fide receptorHumoral responseVirus infectionEntry receptorReceptor utilizationCell tropismInfectionReceptorsVirus-like particlesFide receptorCD300lfNorovirusHNoVCD300ldMajor determinantProteinaceous receptorsVivoMNoV.MNoVPathogenesis
2000
Expression of Human Immunodeficiency Virus Type 1 Gag Protein Precursor and Envelope Proteins from a Vesicular Stomatitis Virus Recombinant: High-Level Production of Virus-like Particles Containing HIV Envelope
Haglund K, Forman J, Kräusslich H, Rose J. Expression of Human Immunodeficiency Virus Type 1 Gag Protein Precursor and Envelope Proteins from a Vesicular Stomatitis Virus Recombinant: High-Level Production of Virus-like Particles Containing HIV Envelope. Virology 2000, 268: 112-121. PMID: 10683333, DOI: 10.1006/viro.1999.0120.Peer-Reviewed Original ResearchMeSH KeywordsAIDS VaccinesAnimalsCell LineDNA, RecombinantGene Products, gagGenetic VectorsHIV Envelope Protein gp120HIV-1HumansMembrane GlycoproteinsMicroscopy, ElectronPlasmidsProtein PrecursorsRecombinant Fusion ProteinsVaccines, AttenuatedVesicular stomatitis Indiana virusViral Envelope ProteinsVirionConceptsHIV virus-like particlesVirus-like particlesEnv proteinHIV-1HIV-1 envelope proteinAntibody-mediated immunityHigh-level productionRecombinant vesicular stomatitis virusVSV particlesHIV Env proteinEnvelope proteinEffective vaccine vectorHIV-like particlesProtein precursorHIV envelopeHigh-level expression vectorVaccine vectorHIV recombinantsVesicular stomatitis virusVirus titersVirus recombinantsVSV G proteinG proteinsStomatitis virusExpression vector
1997
Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge
Sundaram P, Tigelaar R, Brandsma J. Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine 1997, 15: 664-671. PMID: 9178468, DOI: 10.1016/s0264-410x(96)00237-x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, ViralAntigens, ViralBiolisticsCell DivisionCHO CellsCloning, MolecularCottontail rabbit papillomavirusCricetinaeEpitopes, T-LymphocyteInjections, SubcutaneousNeutralization TestsPapillomavirus InfectionsRabbitsT-LymphocytesTumor Virus InfectionsVaccines, SyntheticViral Structural ProteinsViral VaccinesConceptsCottontail rabbit papillomavirusHigh titered antibodiesVaccination of rabbitsCellular proliferative responseMajor capsid protein L1Capsid protein L1Papillomavirus infectionTitered antibodiesDNA vaccineVirus challengeProliferative responseIntracutaneous vaccinationPapilloma formationRabbit papillomavirusVirus-like particlesL1 geneL1 DNARabbitsVaccinationAntibodies
1994
Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA
Rolls M, Webster P, Balba N, Rose J. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 1994, 79: 497-506. PMID: 7954815, DOI: 10.1016/0092-8674(94)90258-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsbeta-GalactosidaseCells, CulturedGenetic VectorsHumansMembrane GlycoproteinsModels, GeneticNeutralization TestsParticle SizeRepliconRNA VirusesRNA-Dependent RNA PolymeraseSemliki forest virusSerial PassageSpecies SpecificityTransfectionViral Envelope ProteinsViral Fusion ProteinsVirus ReplicationConceptsVesicular stomatitis virus glycoproteinVSV G proteinSemliki Forest virusStructural proteinsMembrane-enveloped vesiclesRNA repliconsSFV structural proteinsInfectious particlesViral structural proteinsTissue culture cellsVirus glycoproteinAnimal cellsSelf-replicating RNARNA replicaseG proteinsCulture cellsProteinRepliconVirus-like particlesVesiclesVSV serumCellsGlycoproteinExpressionReplicase
1990
Evolution of nuclear DNA and the occurrence of sequences related to new small chromosomal DNAs in the trypanosomatid genus Endotrypanum
de C.S. Lopes A, Iovannisci D, Petrillo-Peixoto M, McMahon-Pratt D, Beverley S. Evolution of nuclear DNA and the occurrence of sequences related to new small chromosomal DNAs in the trypanosomatid genus Endotrypanum. Molecular And Biochemical Parasitology 1990, 40: 151-161. PMID: 2362601, DOI: 10.1016/0166-6851(90)90037-m.Peer-Reviewed Original ResearchConceptsHybridization probesMolecular karyotype analysisMolecular evolutionary treeComplex hybridization patternDNA restriction fragment patternsRestriction fragment patternsEvolutionary relatednessSequence divergenceDisjunct distributionEvolutionary treeTrypanosomatid parasitesGenus EndotrypanumNuclear DNAChromosomal DNAHybridization patternsRelated sequencesRestriction enzymesChromosomesEndotrypanumFragment patternsKaryotype analysisOccurrence of sequencesDNAGroup B isolatesVirus-like particles
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply